Paul the Octopus: great at predicting, but not much use as a lobbyist for big business |
New hand at the steering wheel |
Marvo liked the idea of patents -- but could never figure out the idea of an enabling disclosure |
So far he only has a little list, relating to the patents for (i) Escitalopram, (ii) Lipitor, (iii) Viagra and (iv) Olanzapine, plus Conor Medsystems v Angiotech. If you have any more examples for his collection, please post them below.
Slightly dyslexic and an occasionally careless reader, tytoc collie has had some trouble convincing himself that the CCC is the Copyright Clearance Center, nothing to do with Copyright Clarence at all. Anyway, a new podcast is available from the CCC's Beyond the Book site: it features a (United States) Suffolk University Law School event in which CCC’s Chris Kenneally speaks with entertainment industry attorney Patti Jones and advertising executive Lenora Cushing; the trio ponder on the way trends in music licensing are changing how rock bands achieve fame and fortune. The podcast lives here but, if you can read more quickly than you can listen, a transcript for slow listeners can be found here.
Berenika Depo's sudden and untimely death last summer (see IPKat obituary here) was a loss not just to Polish intellectual property but to the IP community worldwide. The Kat has just learned from her father Justyn that on 12 January the Polish Chamber of Patent Attorneys is granting Berenika a posthumous distinguished service award, to commemorate her efforts and achievements on behalf of the Polish profession. Also, Berenika's 'Amici Berenicae' Foundation has been established, to further the education talented youngsters in Poland, Tibet and Nepal. You can donate a contribution to the 'Amici Berenicae' Foundation (PLN: 62 2490 0005 0000 4520 7616 3497; Euros - 33 2490 0005 0000 4600 4412 9303; US$ 97 2490 0005 0000 4600 4252 2413; SWIFT code: ALBPPLPW). A book of essays in memory of Berenika is also planned: details will be supplied when they are available.
No comments:
Post a Comment